

PCT/PTG 12 OCT 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number
WO 03/084941 A2(51) International Patent Classification⁷: **C07D 295/18**,
241/24, 211/60, 207/16, A61K 31/40, 31/44, 31/535,
A61P 29/00Basel (CH). NEUMANN, Ulf [DE/CH]; Waldhofstrasse
62, CH-4310 Rheinfelden (CH).

(21) International Application Number: PCT/EP03/03644

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellec-
tual Property, CH-4002 Basel (CH).

(22) International Filing Date: 8 April 2003 (08.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0208176.8 9 April 2002 (09.04.2002) GB(71) Applicant (for all designated States except AT, US): NO-
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR,
TT, UA, US, UZ, VC, VN, YU, ZA, ZW.(84) Designated States (regional): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).(71) Applicant (for AT only): NOVARTIS PHARMA GMBH
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).


Published:

— without international search report and to be republished
upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (for US only): JANSER, Philipp
[CH/CH]; Delsbergerallee 1, CH-4053 Basel (CH).
MILTZ, Wolfgang [DE/CH]; Tessinstrasse 12, CH-4054For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HYDROXAMIC ACID DERIVATIVES



(I)

(57) Abstract: Novel hydroxamic acid derivatives, e.g., of for-
mula (I), wherein R₁, R₂, R₃ and R₄ are as defined, are found to
be useful as pharmaceuticals, e.g., for the suppression of TNF
release and the treatment of autoimmune and inflammatory dis-
eases, e.g., multiple sclerosis and rheumatoid arthritis. Meth-
ods of making the compounds, novel intermediates, and phar-
maceutical compositions comprising the compounds are pro-
vided.